Shots:

• NICE has issued a final appraisal determination (FAD) which recommends UCB’s bimekizumab as a treatment option for adults with severe PsO
• The recommendation is based on four P-III studies i.e BE VIVID- BE RADIANT (P- IIIb)- BE READY & BE SURE that demonstrated the superior efficacy and safety of bimekizumab in adults with PsO against PBO- ustekinumab- secukinumab and adalimumab
• The company expects MHRA’s decision for approval in the next few mos. if approved- NICE will give final technology appraisal guidance & bimekizumab will be available in England and Wales. The therapy is also under review in the EU & US

 to   | Ref: NICE | Image: NICE